ACAD Acadia Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ACAD
Price (delayed)
$23.095
Market cap
$3.87B
P/E Ratio
16.74
Dividend/share
N/A
EPS
$1.38
Enterprise value
$3.68B
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who
Highlights
The company's equity has surged by 65% YoY and by 4.4% QoQ
The quick ratio has surged by 53% year-on-year and by 21% since the previous quarter
The debt has decreased by 9% YoY but it has increased by 6% QoQ
Key stats
What are the main financial stats of ACAD
Market
Valuations
Earnings
Shares outstanding
167.36M
Market cap
$3.87B
Enterprise value
$3.68B
Price to earnings (P/E)
16.74
Price to book (P/B)
5.03
Price to sales (P/S)
3.87
EV/EBIT
13.91
EV/EBITDA
13.24
EV/Sales
3.7
Revenue
$996.28M
Gross profit
$917M
Operating income
$234.87M
Net income
$228.88M
EBIT
$264.85M
EBITDA
$278.16M
Free cash flow
$148.44M
Per share
Balance sheet
Liquidity
EPS
$1.38
EPS diluted
$1.37
Free cash flow per share
$0.89
Book value per share
$4.59
Revenue per share
$5.97
TBVPS
$6.09
Total assets
$1.13B
Total liabilities
$367.13M
Debt
$44.63M
Equity
$765.24M
Working capital
$568.41M
Debt to equity
0.06
Current ratio
2.88
Quick ratio
2.66
Net debt/EBITDA
-0.65
Margins
Efficiency
Dividend
EBITDA margin
27.9%
Gross margin
92%
Net margin
23%
Operating margin
23.6%
Return on assets
21.7%
Return on equity
35.3%
Return on invested capital
64%
Return on capital employed
31.9%
Return on sales
26.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACAD stock price
How has the Acadia Pharmaceuticals stock price performed over time
Intraday
0.2%
1 week
2.37%
1 month
2.64%
1 year
24.5%
YTD
25.86%
QTD
7.07%
Financial performance
How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$996.28M
Gross profit
$917M
Operating income
$234.87M
Net income
$228.88M
Gross margin
92%
Net margin
23%
ACAD's gross profit is up by 22% year-on-year and by 4.7% since the previous quarter
ACAD's revenue is up by 22% YoY and by 4% QoQ
The net margin has decreased by 2.5% QoQ
The operating margin has decreased by 2.1% QoQ
Price vs fundamentals
How does ACAD's price correlate with its fundamentals
Growth
What is Acadia Pharmaceuticals's growth rate over time
Valuation
What is Acadia Pharmaceuticals stock price valuation
P/E
16.74
P/B
5.03
P/S
3.87
EV/EBIT
13.91
EV/EBITDA
13.24
EV/Sales
3.7
The stock's price to earnings (P/E) is 51% less than its last 4 quarters average of 33.9
The company's equity has surged by 65% YoY and by 4.4% QoQ
ACAD's price to book (P/B) is 31% lower than its 5-year quarterly average of 7.3 but 14% higher than its last 4 quarters average of 4.4
ACAD's P/S is 43% below its 5-year quarterly average of 6.8 but 33% above its last 4 quarters average of 2.9
ACAD's revenue is up by 22% YoY and by 4% QoQ
Efficiency
How efficient is Acadia Pharmaceuticals business performance
ACAD's return on invested capital is down by 15% since the previous quarter
The ROE has contracted by 11% from the previous quarter
Acadia Pharmaceuticals's return on assets has decreased by 6% QoQ
Dividends
What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACAD.
Financial health
How did Acadia Pharmaceuticals financials performed over time
The quick ratio has surged by 53% year-on-year and by 21% since the previous quarter
The current ratio has grown by 41% YoY and by 21% from the previous quarter
The debt is 94% lower than the equity
The company's equity has surged by 65% YoY and by 4.4% QoQ
The debt to equity has declined by 45% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.